Bausch + Lomb Corporation (BLCO)
NYSE: BLCOHealth CareOphthalmic GoodsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BLCO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $6.93B
- Forward P/E
- 16.36
- EPS (TTM)
- -$0.32
- Dividend yield
- None
- 52-week range
- 14.65 – 21.40
- Day range
- 19.30 – 20.50
- Volume / Avg
- 871.55K / 660.67K
- Beta
- —
- Shares outstanding
- 357.50M
52-week range
BLCO stock today
Shares of Bausch + Lomb (BLCO) finished lower on Nov 20 at $19.38, a drop of 6.33% or $1.31 per share, versus the S&P 500's 3.70% decline. At this level, BLCO sits in the middle of its 52-week range of $14.65 to $21.40: 9.4% below the high, set on Nov 10, 2026 and 32.3% above the low. BLCO is up 13.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 28.6%.
Bausch + Lomb has posted a net loss over the last twelve months (EPS of -$0.32), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Bausch + Lomb
Company profileBausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing.
- Sector
- Health Care
- Industry
- Ophthalmic Goods
- CEO
- Mr. Thomas J. Appio
- Headquarters
- Vaughan, ON
- Employees
- 13,000
- IPO year
- 2022
- Website
- bausch.com
Financial highlights
Full financialsIn fiscal 2025, Bausch + Lomb generated $5.10 billion in revenue, up 6.5% from fiscal 2024, its 5th consecutive year of revenue growth. Bausch + Lomb reported a net loss of $360.0 million, compared with a loss of $317.0 million a year earlier. Operating margin was 2.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $5.10B | $4.79B | $4.15B | $3.77B | $3.77B |
| Growth | +6.47% | +15.56% | +10.03% | +0.08% | +10.35% |
| Net income | $-360.00M | $-317.00M | $-260.00M | $6.00M | $182.00M |
| EPS (diluted) | $-1.02 | $-0.90 | $-0.74 | $0.02 | $0.52 |
Analyst forecast
ForecastConsensus (15 analysts)
buy
Avg. price target
$21.93+13.16%
- Strong buy 2
- Buy 4
- Hold 8
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 28, 2026
- EPS actual vs est.
- $0.09 vs $0.21
- Surprise
- -57.14%
BLCO news
All BLCO news- Charles River Stock Surges 102.3% in a Year: What's Fueling the Drive?NasdaqCRL, IDXX, PODD, BLCO
- Is This the Right Time to Hold Resmed Stock in Your Portfolio?NasdaqRMD, IDXX, PODD, BLCO
- Quest Diagnostics Stock Gains 49.3% YTD: What's Behind the Rally?NasdaqDGX, IDXX, PODD, BLCO
- Is This the Right Time to Retain Omnicell Stock in Your Portfolio?NasdaqOMCL, IDXX, PODD, BLCO
- Illumina Stock Surges 74.8% in a Year: What's Fueling the Drive?NasdaqILMN, IDXX, PODD, BLCO
- Should You Continue to Hold Medtronic Stock in Your Portfolio?NasdaqMDT, IDXX, PODD, BLCO
- Best Growth Stocks to Buy for November 17thNasdaqEXPE, CR, BLCO
- Best Growth Stocks to Buy for November 13thNasdaqHAS, VLO, BLCO
Bausch + Lomb peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| WRBYWarby Parker Inc. Class A | 23.12 | -4.19% | $2.87B | vs BLCO |
| COOThe Cooper Companies Inc. | 58.88 | -2.40% | $11.20B | vs BLCO |
| EYENational Vision Holdings Inc. | 16.72 | -1.70% | $1.31B | vs BLCO |
| STAASTAAR Surgical Company | 24.22 | -3.24% | $1.22B | vs BLCO |
| RXSTRxSight Inc. | 4.47 | -3.04% | $187.42M | vs BLCO |
| LUCYInnovative Eyewear Inc. | 0.7025 | -0.07% | $6.12M | vs BLCO |
| ALCAlcon Inc. | 74.31 | -0.26% | $35.70B | vs BLCO |
Indexes, lists and sector
Bausch + Lomb stock FAQ
What is Bausch + Lomb's stock price today?
BLCO last traded at $19.38 as of Nov 20, 4:00 PM EST, down 6.33% on the day. Prices are delayed at least 15 minutes.
Who is Bausch + Lomb's CEO?
Mr. Thomas J. Appio is the chief executive officer of Bausch + Lomb Corporation, which has about 13,000 employees.
What is the BLCO 52-week high?
The 52-week high for BLCO is $21.40 and the 52-week low is $14.65. The stock is currently 9.4% below its high.